Access TOC
Download Data
December 2024
The global induced pluripotent stem cells market size is calculated at USD 1.93 billion in 2024, grew to USD 2.13 billion in 2025, and is projected to reach around USD 5.12 billion by 2034. The market is expanding at a CAGR of 10.25% between 2024 and 2034. The rising prevalence of chronic disorders, growing demand for regenerative medicine, and technological advancements drive the market.
Unlock Infinite Advantages: Subscribe to Annual Membership
Induced pluripotent stem cells (iPSCs) are immature cells derived from adult or mature skin or blood cells and can differentiate into any cell type in the body. Due to their ability to propagate indefinitely into any cell type, such as neurons, heart, pancreatic, and liver cells they are widely used in regenerative medicine. Apart from this, they have the potential to model human development and diseases, perform high-throughput drug screening, and develop autologous and allogeneic cell therapies. The most common type of pluripotent stem cells is the embryonic stem cells. Researchers have investigated several proteins that induce or enhance pluripotency in non-pluripotent cells.
The rising incidences or prevalence of chronic disorders necessitate the development of novel therapeutics. This leads to the growing research and development activities globally and rising demand for regenerative medicines. Several government and private organizations fund research projects related to stem cell research owing to their widespread applications in medicine, thereby promoting induced pluripotent stem cells market growth.
Artificial intelligence (AI) has immense potential to revolutionize the healthcare sector. It has already been applied to numerous fields, resulting in improved outcomes. AI technologies have great promise for improving knowledge of how diseases arise and advance, opening the door for potential clinical uses in the future. AI has also been studied in iPSC technology for classifying different cell types, assessing disease-specific phenotypes in iPSC-derived cells, and facilitating drug screening using iPSC. Several researchers are investigating the role of AI and machine learning (ML) in achieving greater objectivity and efficiency in the evaluation process. AI and ML can also be used to monitor cell functionality and conduct genetic analysis. Additionally, these technologies facilitate the identification of specific biomarkers coupled with quantitative gene expression analysis. AI can also be used to manufacture pluripotent stem cells. Hence, AI methodologies are the foundation for future advancements in iPSC technologies.
For instance,
Growing Demand for Regenerative Medicine
The demand for regenerative medicines has been increasing for many decades due to the rising incidences of chronic disorders. Regenerative medicines have been extensively studied for treating chronic disorders such as cancer, diabetes, neurological disorders, heart failure, osteoarthritis, and other disorders. Novel applications for regenerative medicine are continuously evaluated. Regenerative medicine may enable scientists to grow tissues and organs in the laboratory and safely implant them when the body is unable to heal itself. The growing research and development activities related to regenerative medicine boost induced pluripotent stem cells market growth. This has led to an increasing number of clinical trials studying the effects of iPSCs on humans. As of November 2024, about 40 clinical trials related to iPSCs have been registered on clinicaltrials.gov. Additionally, the demand for iPSCs is increasing due to favorable government support and increasing investments & collaborations.
Manufacturing Challenges
The major challenge of the induced pluripotent stem cells market is the high manufacturing cost of iPSC technology. It is estimated that the average cost ranges from $10,000 to $20,000 for generating and expanding an iPSC line, along with all the necessary tests to assess its pluripotency and safety. For clinical purposes, the cost of iPSC cell lines can reach up to $1 million. This limits the affordability of many research organizations in LMICs. Also, the production of iPSCs takes around 4 to 6 months. These manufacturing challenges restrict market growth.
Latest Advancements
The growing demand for iPSCs necessitates novel advancements in the iPSC technology. Apart from deriving expanded applications of iPSCs, researchers are developing novel extraction methods. Small-molecule compounds are developed to generate iPSCs from mouse cells. The chemical reprogramming strategy is a potential future reprogramming strategy for different somatic cells. Disease models are generated from iPSCs to study the mechanisms of human genetic disorders and test the effects of novel drugs. They have huge potential to advance personalized therapy by providing patient-specific models for personalized therapies.
Additionally, iPSC technology can be integrated with genome editing, 3D cell culture systems, and other techniques to advance research. Hence, the use of iPSCs in medicine has a bright future ahead, with prospects for precision medicine breakthroughs, novel treatment development, the development of more sophisticated research models, and integration with other cutting-edge technologies.
By derived cell type, the fibroblasts segment held a dominant presence in the induced pluripotent stem cells market in 2023. Fibroblasts are cells that contribute to the formation of connective tissues. They are commonly used as the primary somatic cell type for generating iPSCs. They are widely preferred due to their high availability, ease of isolation, and simplicity. Additionally, they are comparatively cheap and they can be easily handled. Several companies commercially sell fibroblasts derived from various organs and tissues.
By derived cell type, the hepatocytes segment is expected to grow at the fastest rate in the induced pluripotent stem cells market during the forecast period. Hepatocytes are liver cells that play a vital role in liver function. iPSCs can produce hepatocyte-like cells (HLCs) with homologous phenotypes and physiological functions. The rising incidences of liver disorders and growing research and development activities augment the segment’s growth.
By application, the drug development segment led the global induced pluripotent stem cells market in 2023. iPSCs are widely used as a valuable tool in drug discovery and development as they can be used to model human diseases in a laboratory setting. iPSC platform can also be used to screen drugs based on their efficacy and safety. The growing drug discovery research and demand for personalized medicines boost the segment’s growth. Since these cells have the genetic background of patients, they can be used in developing personalized therapy.
By application, the tissue engineering & regenerative medicine segment is anticipated to grow with the highest CAGR in the market during the studied years. iPSCs have emerged as a promising tool in regenerative medicine and tissue engineering. They provide a new source for tissue engineering and cell-based therapies without the ethical concerns associated with the use of embryos. The growing demand for regenerative medicine, favorable government policies, and increasing investments potentiate the segment’s growth.
By end-use, the pharmaceutical & biotechnology companies segment registered its dominance over the global induced pluripotent stem cells market in 2023. The segment’s growth is attributed to favorable infrastructure, suitable investment, increased collaborations, and the presence of trained professionals. Pharmaceutical & biotech companies perform research activities and follow the regulatory framework for market approval of the iPSC-derived products.
By end-use, the academic & research institutions segment is projected to expand rapidly in the market in the coming years. The growing research and development activities at academic levels and increasing government funding promote the segment’s growth.
North America held the largest share of the induced pluripotent stem cells market in 2023. The state-of-the-art research and development facilities, technological advancements, the presence of key players, and favorable government policies drive the market. U.S. government agencies like the National Institute of Health (NIH) provide funding and support for iPSC research. It is estimated that one in three Americans could potentially benefit from regenerative medicine. Additionally, the increasing number of clinical trials supports the market. As of November 2024, around 18 ongoing clinical trials related to iPSC research were registered on clinicaltrials.gov. The Government of Canada announced an investment in the Stem Cell Network (SCN) organization of $45 million from 2022-2025. Apart from these, major players such as Accelerated Biosciences, Aspen Neuroscience, NEXEL, and Stemson Therapeutics hold a major share of the market.
Asia-Pacific is anticipated to grow at the fastest rate in the induced pluripotent stem cells market during the forecast period. The rising incidences of chronic disorders, favorable government support, and increasing investments & collaborations drive the market. The Chinese government recently lifted restrictions on foreign investments in stem cells, gene therapy, and genetic diagnosis for product registration and manufacturing in four free trade zones. The Indian government also actively supports stem cell research through various guidelines. Additionally, the rising geriatric population in the Asia-Pacific countries is more prone to developing chronic disorders. Japan recorded the highest geriatric population of 36.25 million, accounting for 29.3% of the population. Furthermore, China ranks second in terms of the number of clinical trials based on iPSC research globally. The increasing number of startups in the region, owing to suitable manufacturing facilities, also potentiates market growth.
For instance,
Thomas H.R. Carlsen, CEO of the Novo Nordisk Foundation Cellerator, commented that cell therapies can treat or manage symptoms of chronic diseases, treat the disease itself, or cure with a one-off procedure. He also added that the company is solving issues related to the large-scale manufacturing of cell therapy products and providing hope to people living with chronic diseases.
By Derived Cell Type
By Application
By End-Use
By Region
December 2024
November 2024
November 2024
October 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts